Compare Panacea Biotech with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs TTK HEALTHCARE - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH TTK HEALTHCARE PANACEA BIOTECH/
TTK HEALTHCARE
 
P/E (TTM) x 13.2 10.9 121.7% View Chart
P/BV x 5.1 1.6 326.4% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 PANACEA BIOTECH   TTK HEALTHCARE
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
TTK HEALTHCARE
Mar-19
PANACEA BIOTECH/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3541,215 29.1%   
Low Rs138610 22.7%   
Sales per share (Unadj.) Rs74.6444.4 16.8%  
Earnings per share (Unadj.) Rs6.717.2 38.7%  
Cash flow per share (Unadj.) Rs15.527.6 56.1%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs57.2177.9 32.2%  
Shares outstanding (eoy) m61.2514.13 433.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.1 160.6%   
Avg P/E ratio x36.852.9 69.6%  
P/CF ratio (eoy) x15.933.0 48.0%  
Price / Book Value ratio x4.35.1 83.8%  
Dividend payout %029.0 0.0%   
Avg Mkt Cap Rs m15,06112,894 116.8%   
No. of employees `0002.32.3 100.1%   
Total wages/salary Rs m1,4711,307 112.5%   
Avg. sales/employee Rs Th1,973.62,715.7 72.7%   
Avg. wages/employee Rs Th635.6565.3 112.4%   
Avg. net profit/employee Rs Th176.8105.4 167.7%   
INCOME DATA
Net Sales Rs m4,5676,279 72.7%  
Other income Rs m4578 57.8%   
Total revenues Rs m4,6126,356 72.6%   
Gross profit Rs m2,030496 409.5%  
Depreciation Rs m540147 368.1%   
Interest Rs m1,04834 3,101.5%   
Profit before tax Rs m486393 123.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m77149 51.8%   
Profit after tax Rs m409244 167.9%  
Gross profit margin %44.47.9 563.0%  
Effective tax rate %15.937.9 41.8%   
Net profit margin %9.03.9 230.8%  
BALANCE SHEET DATA
Current assets Rs m2,4152,717 88.9%   
Current liabilities Rs m9,0771,571 577.9%   
Net working cap to sales %-145.918.3 -799.0%  
Current ratio x0.31.7 15.4%  
Inventory Days Days6532 202.4%  
Debtors Days Days7147 152.0%  
Net fixed assets Rs m8,333991 840.9%   
Share capital Rs m61141 43.4%   
"Free" reserves Rs m3,4432,373 145.1%   
Net worth Rs m3,5042,514 139.4%   
Long term debt Rs m4613 13,564.7%   
Total assets Rs m13,7554,158 330.8%  
Interest coverage x1.512.6 11.6%   
Debt to equity ratio x0.10 9,733.4%  
Sales to assets ratio x0.31.5 22.0%   
Return on assets %10.66.7 158.8%  
Return on equity %11.79.7 120.5%  
Return on capital %38.716.9 228.5%  
Exports to sales %20.93.6 582.3%   
Imports to sales %8.10.5 1,652.1%   
Exports (fob) Rs m954225 423.6%   
Imports (cif) Rs m37231 1,201.7%   
Fx inflow Rs m1,203225 534.2%   
Fx outflow Rs m46771 656.3%   
Net fx Rs m736154 477.9%   
CASH FLOW
From Operations Rs m1,049173 605.9%  
From Investments Rs m-5497 -55.4%  
From Financial Activity Rs m-1,011-307 329.1%  
Net Cashflow Rs m-20-38 52.3%  

Share Holding

Indian Promoters % 74.5 65.4 113.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 3.7 16.2%  
FIIs % 1.3 5.2 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 25.8 91.5%  
Shareholders   10,259 12,723 80.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   WOCKHARDT  ABBOTT INDIA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  TORRENT PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 71.7% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (3QFY20); Net Profit Down 8.3% (Quarterly Result Update)

Jan 30, 2020 | Updated on Jan 30, 2020

For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Apr 20, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS